Private company
Sofgen Pharma S.A.
Pharmaceutical preparations company. Summary from the record
Last updated Oct 19, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
51.2%Gross margin2
-14.4%Operating margin2
-18.3%Net margin2
-11.8%Revenue growth, 20242
$69.1MFree cash flow2
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Cost of revenue49¢$182.3M
- Other costs36¢$132.7M
- Interest11¢$42.5M
- Income tax4¢$16.3M
Out of $373.8M in revenue.2 The company lost money this year.
Where each dollar of operating cash went, fiscal 2024
- Capital spending22¢$19.4M
- Kept or used elsewhere78¢$69.1M
Out of $88.4M of cash from operations.2
Financial statements
No quarterly figures reported.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $324.8M4 | $331.5M5 | $403.7M6 | $403.2M2 | $423.7M2 | $373.8M2 | |
| Cost of revenue | $173.7M6 | $168.1M2 | $185.8M2 | $182.3M2 | |||
| Gross profit | $182.5M4 | $191.3M5 | $230.1M6 | $235.1M2 | $238.0M2 | $191.5M2 | |
| Operating income | -$15.1M6 | $9.8M2 | $72.1M2 | -$54.0M2 | |||
| Interest | $85.6M6 | $25.8M2 | $40.9M2 | $42.5M2 | |||
| Income before tax | -$93.9M6 | $47.7M2 | $46.0M2 | -$84.6M2 | |||
| Income tax | $13.1M6 | $11.6M2 | $5.6M2 | -$16.3M2 | |||
| Net income | -$17.0M4 | -$10.4M5 | -$107.0M6 | $36.1M2 | $40.3M2 | -$68.3M2 | |
| Earnings per share | -$0.184 | -$0.115 | -$1.096 | $0.362 | $0.402 | -$0.682 | |
| Earnings per share (diluted) | -$0.115 | -$1.096 | $0.362 | $0.402 | -$0.682 | ||
| Shares (weighted, basic) | 98.1K shares6 | 101.1K shares2 | 101.0K shares2 | 100.3K shares2 | |||
| Shares (weighted, diluted) | 98.1K shares6 | 101.1K shares2 | 101.0K shares2 | 100.3K shares2 |
No quarterly figures reported.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash | $2.8M4 | $2.0M5 | $4.2M6 | $72.1M2 | $43.0M2 | $17.5M2 | $30.3M2 |
| Receivables | $100.0M6 | $106.4M6 | $124.9M2 | $78.3M2 | |||
| Inventory | $81.6M6 | $99.8M6 | $101.8M2 | $76.5M2 | |||
| Current assets | $284.9M6 | $279.3M6 | $275.6M2 | $216.7M2 | |||
| Property, plant and equipment | $71.4M6 | $70.6M6 | $91.0M2 | $93.7M2 | |||
| Goodwill | $6.8M6 | $5.8M2 | $06 | ||||
| Intangible assets | $30.1M6 | $32.2M6 | $42.9M2 | $30.3M2 | |||
| Total assets | $337.7M4 | $359.5M4 | $450.3M6 | $442.5M6 | $472.5M2 | $411.7M2 | |
| Accounts payable | $87.4M6 | $90.6M6 | $93.1M2 | $107.0M2 | |||
| Short-term debt | $224.3M6 | $257.9M6 | $268.4M2 | $226.6M2 | |||
| Current liabilities | $356.3M6 | $386.3M6 | $433.6M2 | $415.9M2 | |||
| Long-term debt | $29.0M6 | $29.2M6 | $31.1M2 | $41.4M2 | |||
| Long-term liabilities | $164.0M6 | $93.4M6 | $39.7M2 | $47.9M2 | |||
| Retained earnings | -$465.9M6 | -$432.5M6 | -$396.3M2 | -$471.4M2 | |||
| Shareholders’ equity | -$127.7M4 | -$243.9M5 | -$282.7M6 | -$70.0M2 | -$37.1M2 | -$736.0K2 | -$52.1M2 |
| Shares outstanding | 112.8M shares4 | 112.8M shares5 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash from operations | $68.3M4 | $70.9M5 | $35.5M6 | $15.6M2 | $107.6M2 | $88.4M2 | |
| Capital spending | $11.8M4 | $7.7M5 | $15.4M6 | $23.2M2 | $20.3M2 | $19.4M2 | |
| Free cash flow | $56.5M | $63.2M | $20.0M | -$7.6M | $87.3M | $69.1M | |
| Cash from investing | -$24.9M6 | -$32.4M2 | -$34.6M2 | -$26.8M2 | |||
| Dividends paid | $200.0K6 | $300.0K6 | |||||
| Share buybacks | $45.0M6 | $06 | $06 | ||||
| Cash from financing | $57.8M6 | -$12.8M2 | -$97.8M2 | -$50.4M2 |
Leadership
Who has led Sofgen Pharma S.A., and when. Pick a name to see everywhere that person has worked.
Chief executive
2025
- Chief executive officerAngelini Melissa Andreia Silva Mar 18, 2026 to now7
- Chief executive officerRuben Minski Oct 8, 2021 to Oct 8, 20218
Board members and other officers (11)
- Chief Commercial OfficerLuis Alberto Palacios Mar 30, 2026 to now9
- Board memberNicolas Alexandre Weinstein Mar 18, 2026 to now10
- Board memberCamacho Carlos Romero Mar 26, 2026 to now11
- Board memberClaro Manuel Jose Vial Mar 26, 2026 to now12
- Board memberAlberto Eguiguren Mar 30, 2026 to now13
- Board memberIragorri Carlos Garcia Mar 30, 2026 to now14
- Board memberJaramillo Daniel Augusto Bernal Mar 30, 2026 to now15
- Board memberMuniz Fernando Sebastian Moreira Mar 30, 2026 to now16
- Board memberJose Minski Oct 8, 2021 to Oct 8, 202117
- Board memberRuben Minski Oct 8, 2021 to Oct 8, 20218
- Board memberAlexandre Weinstein Manieu Oct 12, 2021 to now18
Former names
- Procaps Group, S.A.Jun 21, 2021 to Nov 19, 20253
Timeline
Filings
148 filings to the SEC since October 2021: 5 annual reports, 14 insider forms, 21 large holders, 108 other. The latest 20:
- Mar 30, 20263 EDGAR
- Mar 30, 20263 EDGAR
- Mar 30, 20263 EDGAR
- Mar 30, 20263 EDGAR
- Mar 30, 20263 EDGAR
- Mar 26, 20263 EDGAR
- Mar 26, 20263 EDGAR
- Mar 19, 20263 EDGAR
- Mar 18, 20263 EDGAR
- Mar 18, 20263 EDGAR
- Mar 16, 202615-12G EDGAR
- Mar 16, 202620-F ANNUAL REPORT EDGAR
- Dec 5, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Nov 19, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 3, 202520-F EDGAR
- Aug 1, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 14, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 13, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 1, 2025NT 20-F NOTIFICATION OF LATE FILING EDGAR
- Apr 28, 2025SCHEDULE 13D EDGAR
The 148 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- S.a. BecarilSCHEDULE 13D, 1 filing Apr 28, 202519
- Project S.a. ChemoSCHEDULE 13D, 1 filing Apr 25, 202520
- Flying Fish Ventures L.P.SCHEDULE 13D, 1 filing Apr 22, 202521
- Thomas Commercial S.a. SaintSCHEDULE 13D, 1 filing Apr 22, 202522
- Hoche Partners Pharma Holding S.A.SCHEDULE 13D/A, 15 filings Oct 12, 2021 to Apr 16, 202523
- International Finance CorpSC 13G, 1 filing Feb 14, 202224
- SOGNATORE TRUSTSC 13D, 1 filing Oct 12, 202125
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARCamacho Carlos Romero, Board member
- 12SEC EDGARClaro Manuel Jose Vial, Board member
- 13SEC EDGARAlberto Eguiguren, Board member
- 14SEC EDGARIragorri Carlos Garcia, Board member
- 15
- 16
- 17SEC EDGARJose Minski, Board member
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25